10 results
DEF 14A
CHRO
Chromocell Therapeutics Corp
26 Sep 24
Definitive proxy
5:08pm
On February 15, 2024, the Company effected a 9-for-1 reverse stock split of its outstanding Common Stock (the “Stock Split”). All share amounts in this Proxy Statement have been retroactively adjusted to reflect the Stock Split.
Shares Beneficially Owned | ||||||
Shares of Common Stock Beneficially Owned | Percentage of Common Stock Beneficially Owned | |||||
Name of and Address of Beneficial Owner(1): | ||||||
Directors and executive officers | ||||||
Francis Knuettel II(2) | 219,216 | 3.7% | ||||
Ezra Friedberg(3) | 557,118 | 9.6% | ||||
Todd Davis(4) | 90,853 | 1.6% | ||||
Richard Malamut(5) | 30,132 | *% | ||||
Chia-Lin Simmons(6) | 22,919 | *% | ||||
Eric Lang(7) | 27,434 | *% | ||||
All executive officers and directors as a group (6 persons) | 947,672 | 16.4% | ||||
5% or greater stockholders: | ||||||
Chromocell Corporation(8) | 1,093,854 | 19.0% | ||||
Boswell Prayer Ltd(9) | 471,592 | 8.2% | ||||
Motif Pharmaceuticals Ltd.(10) | 483,406 | 8.4% | ||||
Balmoral Financial Group LLC(11) | 520,719 | 9.0% | ||||
AME Equities LLC(12) | 369,178 | 6.4% | ||||
Aperture Healthcare Ventures Ltd.(13) | 444,071 | 7.7% | ||||
Benuvia Operations, LLC (“Benuvia”)(14) | 384,226 | 6.7% | ||||
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp
16 Apr 24
Annual report
4:48pm
Name of and Address of Beneficial Owner(1): | Shares of Common Stock Beneficially Owned | Percentage of Common Stock Beneficially Owned | ||||||
Directors and executive officers | ||||||||
Francis Knuettel II (2) | 177,070 | 3.0 | % | |||||
Ezra Friedberg (3) | 529,054 | 9.0 | % | |||||
Todd Davis (4) | 68,060 | 1.2 | % | |||||
Richard Malamut (5) | 8,335 | *% | ||||||
Chia-Lin Simmons (6) | 8,335 | *% | ||||||
Eric Lang (7) | 8,074 | *% | ||||||
All executive officers and directors as a group (6 persons) | 768,367 | 13.1 | % | |||||
5% or greater stockholders: | ||||||||
Chromocell Corporation (8) | 1,093,854 | 18.6 | % | |||||
Boswell Prayer Ltd (9) | 471,592 | 8.0 | % | |||||
Motif Pharmaceuticals Ltd. (10) | 483,406 | 8.2 | % | |||||
Balmoral Financial Group LLC (11) | 520,719 | 8.9 | % | |||||
AME Equities LLC (12) | 369,178 | 6.3 | % | |||||
Aperture Healthcare Ventures Ltd. (13) | 443,071 | 7.6 | % | |||||
Benuvia Operations, LLC (15) | 384,226 | 6.5 | % |
- Prev
- 1
- Next